Lomifylline

DB18002

small molecule approved

Deskripsi

Struktur Molekul 2D

Berat 278.312
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

369 Data
Regadenoson Lomifylline may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Lomifylline can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Lomifylline.
Allopurinol The serum concentration of Lomifylline can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Lomifylline can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Lomifylline can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Lomifylline can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Lomifylline can be increased when Lomifylline is used in combination with Febuxostat.
Fluvoxamine The metabolism of Lomifylline can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Lomifylline is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Lomifylline is combined with Indacaterol.
Isoniazid The serum concentration of Lomifylline can be increased when it is combined with Isoniazid.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Lomifylline.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Lomifylline.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Lomifylline.
Mexiletine The metabolism of Lomifylline can be decreased when combined with Mexiletine.
Olodaterol Lomifylline may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Lomifylline.
Pentoxifylline The serum concentration of Lomifylline can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Lomifylline can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Lomifylline can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Lomifylline can be increased when it is combined with Propafenone.
Quinine The serum concentration of Lomifylline can be increased when it is combined with Quinine.
Quinidine The serum concentration of Lomifylline can be increased when it is combined with Quinidine.
Riociguat Lomifylline may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Lomifylline can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Lomifylline can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Lomifylline.
Probenecid The serum concentration of Lomifylline can be increased when it is combined with Probenecid.
Isoprenaline The serum concentration of Lomifylline can be decreased when it is combined with Isoprenaline.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Lomifylline.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Lomifylline.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Lomifylline.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Lomifylline.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Lomifylline.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Lomifylline.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Lomifylline.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Lomifylline.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Lomifylline.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Lomifylline.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Lomifylline.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Lomifylline.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Lomifylline.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Lomifylline.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Lomifylline.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Lomifylline.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Lomifylline.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lomifylline.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Lomifylline.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Lomifylline.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Lomifylline.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Lomifylline.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Lomifylline.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Lomifylline.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Lomifylline.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Lomifylline.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Lomifylline.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Lomifylline.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Lomifylline.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Lomifylline.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Lomifylline.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Lomifylline.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Lomifylline.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Lomifylline.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Lomifylline.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Lomifylline.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Lomifylline.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Lomifylline.
Levonordefrin The risk or severity of adverse effects can be increased when Levonordefrin is combined with Lomifylline.
Naphazoline The risk or severity of adverse effects can be increased when Naphazoline is combined with Lomifylline.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Lomifylline.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Lomifylline.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Lomifylline.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Lomifylline.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Lomifylline.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Lomifylline.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Lomifylline.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Lomifylline.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Lomifylline.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Lomifylline.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Lomifylline.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Lomifylline.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Lomifylline.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Lomifylline.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Lomifylline.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Lomifylline.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Lomifylline.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Lomifylline.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Lomifylline.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Lomifylline.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Lomifylline.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Lomifylline.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Lomifylline.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Lomifylline.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Lomifylline.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Lomifylline.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Lomifylline.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Lomifylline.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Lomifylline.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Lomifylline.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul